Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study
Go back to Pfizer's RSV vaccine shows benefit in immuno-compromised adults in study| Pfizer Inc. (NYSE: PFE) | Delayed: 27.80 -0.22 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.02 | 52 Week High | $37.39 | |||
| Open | $28.00 | 52 Week Low | $28.25 | |||
| Day High | $28.02 | P/E | 16.85 | |||
| Day Low | $27.77 | EPS | $1.65 | |||
| Volume | 12,777,762 | |||||
